Deguchi K, Yokota N, Koguchi M, Suzuki Y, Fukayama S, Ishihara R, Oda S, Tanaka S, Nakane Y, Fukumoto T
Section of Studies, Tokyo Clinical Research Center.
Jpn J Antibiot. 1995 Apr;48(4):529-47.
Antimicrobial activities were examined for sulbactam/ampicillin (SBT/ABPC) against clinically isolated microbial strains in 1987, 1990, 1994. Besides, the beta-lactamase productivity and MICs of these strains were measured, and the following conclusions were obtained. 1. The ratio of beta-lactamase producing strains were 90% of methicillin (DMPPC)-susceptible Staphylococcus aureus subsp. aureus (MSSA), about 80% of DMPPC-resistant S. aureus (MRSA), 100% of Escherichia coli, Klebsiella pneumoniae subsp. pneumoniae and Proteus mirabilis, 95% of Moraxella subgenus Branhamella catarrhalis and 15-20% of Haemophilus influenzae. Several kinds of beta-lactamase productivity were observed. 2. Antimicrobial activities of SBT/ABPC against beta-lactamase producing strains of MSSA, M. (B.) catarrhalis, H. influenzae, and almost all of Enterobacteriaceae were stronger than those of ampicillin (ABPC) and piperacillin (PIPC), but antimicrobial activities of SBT/ABPC were weak against MRSA and cephems (CEPs)-resistant strains detected in some of Enterobacteriaceae. 3. It appeared that benzylpenicillin (PCG)-insensitive Streptococcus pneumoniae (PISP) or PCG-resistant S. pneumoniae (PRSP) and CEPs-resistant Escherichia coli increased year by year. 4. Antimicrobial activities of SBT/ABPC were strong against Streptococcus pyogenes, S. pneumoniae, M. (B.) catarrhalis and H. influenzae including beta-lactamase producing strains. Additionally, beta-lactamase inhibiting effect of SBT was observed against beta-lactamase produced by S. aureus and K. pneumoniae which demonstrate indirect pathogenicity. Thus, SBT/ABPC is an injectable antibiotic that is expected to demonstrate clinical usefulness, especially as the first line drug for the respiratory tract infections that are community-acquired.
1987年、1990年和1994年对舒巴坦/氨苄西林（SBT/ABPC）针对临床分离的微生物菌株的抗菌活性进行了研究。此外，还测定了这些菌株的β-内酰胺酶产生率和最低抑菌浓度（MIC），并得出以下结论。1. 产β-内酰胺酶菌株的比例在甲氧西林（DMPPC）敏感的金黄色葡萄球菌亚种金黄色葡萄球菌（MSSA）中为90%，在DMPPC耐药的金黄色葡萄球菌（MRSA）中约为80%，在大肠埃希菌、肺炎克雷伯菌亚种肺炎克雷伯菌和奇异变形杆菌中为100%，在莫拉克斯菌属卡他莫拉菌中为95%，在流感嗜血杆菌中为15 - 20%。观察到了几种β-内酰胺酶产生率情况。2. SBT/ABPC对MSSA、卡他莫拉菌、流感嗜血杆菌以及几乎所有肠杆菌科产β-内酰胺酶菌株的抗菌活性强于氨苄西林（ABPC）和哌拉西林（PIPC），但SBT/ABPC对MRSA以及在某些肠杆菌科中检测到的对头孢菌素（CEPs）耐药的菌株抗菌活性较弱。3. 苯唑西林（PCG）不敏感的肺炎链球菌（PISP）或PCG耐药的肺炎链球菌（PRSP）以及对CEPs耐药的大肠埃希菌似乎逐年增加。4. SBT/ABPC对化脓性链球菌、肺炎链球菌、卡他莫拉菌和流感嗜血杆菌（包括产β-内酰胺酶菌株）抗菌活性强。此外，观察到SBT对金黄色葡萄球菌和肺炎克雷伯菌产生的具有间接致病性的β-内酰胺酶有抑制作用。因此，SBT/ABPC是一种有望显示临床实用性的注射用抗生素，尤其是作为社区获得性呼吸道感染的一线药物。
